PCSK9 Biology, PCSK9 Inhibitors, Cardiovascular Outcomes, and Pleiotropic Effects: Scoping Review with ☸️SAIMSARA
SAIMSARA Journal · 06.06.2026 · 1 (1)
DOI: 10.62487/saimsarac25dcb0d ↗Kurz gefasst
Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 06.06.2026. Die Arbeit nennt 642 Literaturangaben.
Abstract (Originalsprache)
To synthesize current evidence regarding PCSK9. The review uses 642 references and builds its evidence map from 3450 original studies with 1149089216 total participants/sample observations (topic-deduplicated ΣN). The mapped evidence supports PCSK9 as a systems-level regulator whose clinical relevance extends well beyond LDL-receptor degradation, with the most robust and recurrent signal being substantial LDL-C lowering (approximately 50–65%) and reduced cardiovascular events across monoclonal antibody, siRNA, and emerging oral and gene-editing modalities. Recurrent LDLR-independent signals in inflammation, thrombosis, and tumor immunity suggest pleiotropic actions that may broaden therapeutic relevance but also introduce context-specific uncertainties in sepsis, pregnancy, neurobiology, and tissue homeostasis. Practically, these findings indicate that PCSK9 inhibition is most informative when interpreted within cardiovascular, metabolic, and renal phenotypes, while real-world uptake remains constrained by access and adherence barriers. Future research should prioritize prospective trials that disentangle LDL-C-mediated from pleiotropic effects and establish population-specific safety in domains where current evidence remains heterogeneous.
Zitieren
APA
(2026). PCSK9 Biology, PCSK9 Inhibitors, Cardiovascular Outcomes, and Pleiotropic Effects: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsarac25dcb0d
Vancouver
PCSK9 Biology, PCSK9 Inhibitors, Cardiovascular Outcomes, and Pleiotropic Effects: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsarac25dcb0d
BibTeX
@article{euvimed2026,
title = {PCSK9 Biology, PCSK9 Inhibitors, Cardiovascular Outcomes, and Pleiotropic Effects: Scoping Review with ☸️SAIMSARA},
journal = {SAIMSARA Journal},
year = {2026},
volume = {1},
number = {1},
doi = {10.62487/saimsarac25dcb0d}
}
EUVIMED